Solid Biosciences Shares Outstanding History (SLDB)
Solid Biosciences reported 79.0M shares outstanding at the end of fiscal 2025.
View full Solid Biosciences company overviewSolid Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 79.0M | 38.5M | +95.14% |
| 2024 | 2024-12-31 | 40.5M | 20.1M | +98.50% |
| 2023 | 2023-12-31 | 20.4M | 829,874 | +4.24% |
| 2022 | 2022-12-31 | 19.6M | 12.2M | +165.86% |
| 2021 | 2021-12-31 | 7.4M | 1.7M | +29.33% |
| 2020 | 2020-12-31 | 5.7M | 2.6M | +84.60% |
| 2019 | 2019-12-31 | 3.1M | 707,192.437 | +29.79% |
| 2018 | 2018-12-31 | 2.4M | 2.4M | — |
| 2017 | 2017-12-31 | 0 | — | — |
Solid Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 105.1M | 27.5M | +35.47% |
| Q1 2026 | 2026-03-31 | 98.4M | 20.9M | +26.97% |
| Q4 2025 | 2025-12-31 | 79.0M | 38.5M | +95.14% |
| Q3 2025 | 2025-09-30 | 77.9M | 39.0M | +100.06% |
| Q2 2025 | 2025-06-30 | 77.6M | 39.1M | +101.30% |
| Q1 2025 | 2025-03-31 | 77.5M | 39.7M | +104.83% |
| Q4 2024 | 2024-12-31 | 40.5M | 20.1M | +98.50% |
| Q3 2024 | 2024-09-30 | 38.9M | 18.9M | +94.05% |
| Q2 2024 | 2024-06-30 | 38.6M | 18.5M | +92.33% |
| Q1 2024 | 2024-03-31 | 37.8M | 18.3M | +93.29% |
| Q4 2023 | 2023-12-31 | 20.4M | 829,874 | +4.24% |
| Q3 2023 | 2023-09-30 | 20.1M | 19.6M | +3874.86% |
| Q2 2023 | 2023-06-30 | 20.0M | 12.5M | +164.83% |
| Q1 2023 | 2023-03-31 | 19.6M | 12.0M | +159.03% |
| Q4 2022 | 2022-12-31 | 19.6M | 12.2M | +164.54% |
| Q3 2022 | 2022-09-30 | 504,716.427 | −6.9M | −93.17% |
| Q2 2022 | 2022-06-30 | 7.6M | 178,803.302 | +2.42% |
| Q1 2022 | 2022-03-31 | 7.6M | 167,012.508 | +2.26% |
| Q4 2021 | 2021-12-31 | 7.4M | 1.7M | +29.97% |
| Q3 2021 | 2021-09-30 | 7.4M | 4.3M | +138.85% |
| Q2 2021 | 2021-06-30 | 7.4M | 4.3M | +139.84% |
| Q1 2021 | 2021-03-31 | 7.4M | 4.3M | +139.39% |
| Q4 2020 | 2020-12-31 | 5.7M | 2.6M | +84.60% |
| Q3 2020 | 2020-09-30 | 3.1M | 12,031.525 | +0.39% |
| Q2 2020 | 2020-06-30 | 3.1M | 709,441.359 | +29.91% |
| Q1 2020 | 2020-03-31 | 3.1M | 713,939.27 | +30.09% |
| Q4 2019 | 2019-12-31 | 3.1M | 707,192.437 | +29.79% |
| Q3 2019 | 2019-09-30 | 3.1M | 707,954.428 | +29.82% |
| Q2 2019 | 2019-06-30 | 2.4M | −3,075.166 | −0.13% |
| Q1 2019 | 2019-03-31 | 2.4M | −4,152.526 | −0.17% |
| Q4 2018 | 2018-12-31 | 2.4M | 2.4M | — |
| Q3 2018 | 2018-09-30 | 2.4M | — | — |
| Q2 2018 | 2018-06-30 | 2.4M | — | — |
| Q1 2018 | 2018-03-31 | 2.4M | — | — |
| Q4 2017 | 2017-12-31 | 0 | — | — |
Solid Biosciences shares outstanding trends
Over the last five reported fiscal years, Solid Biosciences's shares outstanding moved from 5.7M to 79.0M, a change of 73.3M. The latest reported quarter, Q2 2026, shows 105.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Solid Biosciences filings at SEC.gov ↗